CJC-1295 + Ipamorelin
Research Peptide Blend — For Research Use Only
CJC-1295 + Ipamorelin is a research combination of modified GRF 1-29 (CJC-1295, CAS 863288-34-0) and ipamorelin (CAS 170851-70-4). These peptides engage distinct receptor pathways in laboratory signaling models. Research compound — not for human use.
Product Details
- Compound: CJC-1295 (No DAC) + Ipamorelin
- Contents: Modified GRF 1-29 and Ipamorelin
- Testing: Current batch PP2605-008 has an ILS full-panel report with 99.35% mean HPLC purity and 10.45mg mean combined peptide content. The original report also lists the individual component amounts. Earlier Janoshik amount and endotoxin reports cover batches PP2602-008AA and PP2602-008AB.
- Form: Lyophilized powder
- Size: 10mg total (5mg + 5mg)
CJC-1295 + Ipamorelin documentation path
This blend listing separates component identity, vial composition, and batch documentation so researchers can review the materials without relying on protocol-style claims.
- Composition: modified GRF 1-29 / CJC-1295 component plus Ipamorelin component.
- Documentation: review available COA records and Quality & Testing.
Research use only. This page does not provide dosing, administration, reconstitution, treatment, hormone-use, or human-use guidance.





